IRIS
BORDI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.631
AS - Asia 2.131
EU - Europa 1.644
SA - Sud America 399
AF - Africa 117
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 6.929
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.568
SG - Singapore 913
CN - Cina 576
IT - Italia 407
BR - Brasile 321
SE - Svezia 286
IE - Irlanda 271
HK - Hong Kong 224
DE - Germania 159
VN - Vietnam 159
NL - Olanda 100
ZA - Sudafrica 76
RU - Federazione Russa 74
FR - Francia 66
AT - Austria 62
FI - Finlandia 59
IN - India 55
GB - Regno Unito 54
CA - Canada 36
AR - Argentina 35
BD - Bangladesh 32
TR - Turchia 29
ID - Indonesia 24
JP - Giappone 20
CI - Costa d'Avorio 17
MX - Messico 17
CZ - Repubblica Ceca 15
IQ - Iraq 15
KR - Corea 15
BE - Belgio 14
EC - Ecuador 14
IR - Iran 12
PL - Polonia 12
UA - Ucraina 12
ES - Italia 11
CO - Colombia 10
LT - Lituania 9
PK - Pakistan 9
TN - Tunisia 9
MA - Marocco 7
CL - Cile 6
LU - Lussemburgo 6
UZ - Uzbekistan 6
IL - Israele 5
SA - Arabia Saudita 5
AU - Australia 4
AZ - Azerbaigian 4
BG - Bulgaria 4
EG - Egitto 4
KZ - Kazakistan 4
PY - Paraguay 4
VE - Venezuela 4
AL - Albania 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
JO - Giordania 3
OM - Oman 3
PE - Perù 3
BH - Bahrain 2
CH - Svizzera 2
CR - Costa Rica 2
GR - Grecia 2
KG - Kirghizistan 2
MD - Moldavia 2
MY - Malesia 2
NO - Norvegia 2
NP - Nepal 2
RO - Romania 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DZ - Algeria 1
GE - Georgia 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KH - Cambogia 1
LV - Lettonia 1
ME - Montenegro 1
MK - Macedonia 1
MN - Mongolia 1
NG - Nigeria 1
PA - Panama 1
PH - Filippine 1
PT - Portogallo 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TW - Taiwan 1
UY - Uruguay 1
Totale 6.929
Salva come PNG Salva come JPEG
Città #
Singapore 503
Ashburn 463
Dallas 349
Chandler 302
Dublin 268
Hong Kong 221
Santa Clara 163
Beijing 153
Boardman 117
Parma 99
New York 94
Munich 84
Shanghai 84
Los Angeles 82
Johannesburg 74
Ann Arbor 60
Ho Chi Minh City 51
Vienna 50
Princeton 46
Milan 43
Hanoi 41
Hefei 39
Bologna 37
Moscow 36
Marseille 30
Helsinki 29
São Paulo 28
Des Moines 26
Columbus 25
Wilmington 25
Nanjing 20
Turku 20
Chicago 19
The Dalles 19
Buffalo 18
Denver 18
Jakarta 18
Seattle 18
Verona 18
Abidjan 17
Bremen 17
Dearborn 17
Tokyo 17
Frankfurt am Main 16
Nuremberg 16
San Jose 16
Montreal 15
Seoul 15
Izmir 14
Atlanta 13
Jinan 13
Guangzhou 12
Redondo Beach 12
Rome 12
West Jordan 12
Brno 11
Modena 11
Poplar 11
Warsaw 11
Amsterdam 10
Changsha 10
Chennai 10
Council Bluffs 10
Brooklyn 9
London 9
Redmond 9
Rio de Janeiro 9
Tianjin 9
Bengaluru 8
Brussels 8
Chongqing 8
Istanbul 8
Manchester 8
Phoenix 8
Pune 8
Stockholm 8
Trento 8
Biên Hòa 7
Boston 7
Brasília 7
Kunming 7
Toronto 7
Belo Horizonte 6
Curitiba 6
Düsseldorf 6
Falls Church 6
Fremont 6
Haiphong 6
Houston 6
Kyiv 6
Louvain-la-Neuve 6
Nanchang 6
Quito 6
Reggio Emilia 6
Shenyang 6
Tashkent 6
Baghdad 5
Bolzano 5
Da Nang 5
Dhaka 5
Totale 4.364
Salva come PNG Salva come JPEG
Nome #
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 178
227P Sexual dimorphism in immune profile of early and advanced NSCLC 174
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 165
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 164
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 158
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 148
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 143
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 140
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 140
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 138
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 138
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 133
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 130
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 129
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 128
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 124
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 123
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 121
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 119
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 119
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 115
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 115
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 114
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 113
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin 111
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 111
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer 107
2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC 106
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 105
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 105
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 104
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 104
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 101
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 100
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 99
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 99
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 96
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 93
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: A study on circulating tumor DNA 93
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 93
Crizotinib resensitization by compound mutation 91
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 89
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 87
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 84
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 83
Narrative literature and cancer: improving the doctor-patient relationship 80
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 80
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 77
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 75
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 74
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 71
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 69
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 68
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance 68
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 63
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: Patient selection and perspectives 62
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study 61
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib 61
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 60
Emerging role of gefitinib in the treatmentof non-small-cell lung cancer (NSCLC) 59
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 57
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: Implications for personalised treatment 57
Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer 54
Enteral administration of tkis: Report of a response to ceritinib in an alk-positive nsclc patient and literature review 53
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 52
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: A case report 50
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study 48
Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: A case report 46
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C-mutated advanced non-small cell lung cancer 45
Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH 44
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 42
Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors 40
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 34
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 33
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 30
Totale 7.043
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.623
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.623
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202160 0 0 0 0 0 10 7 9 20 5 4 5
2021/2022255 2 10 6 17 5 6 48 16 8 4 25 108
2022/20231.119 128 140 58 93 115 120 16 65 311 4 51 18
2023/2024632 30 29 20 22 52 133 67 42 42 44 44 107
2024/20251.868 50 115 160 142 147 180 137 81 169 173 145 369
2025/20262.739 373 343 697 490 588 248 0 0 0 0 0 0
Totale 7.043